Search results
Results from the WOW.Com Content Network
Pore-C workflow. Many methods to characterize the 3D genome are variations on 3C technology. [5] Like other 3C-based technologies, [5] Pore-C seeks to characterize the architecture of the 3D genome by determining which genomic loci are in close spatial proximity (within ~200 nm). [2]
Another foundation for nanopore sequencing was the work of Hagan Bayley's team, who from the 1990s independently developed stochastic sensing, a technique that measures the change in an ionic current passing through a nanopore to determine the concentration and identity of a substance. By 2005 Bayley had made progress with the DNA sequencing ...
The observation that a passing strand of DNA containing different bases corresponds with shifts in current values has led to the development of nanopore sequencing. [14] Nanopore sequencing can occur with bacterial nanopores as mentioned in the above section as well as with the Nanopore sequencing device(s) is created by Oxford Nanopore ...
16S ribosomal RNA (or 16S rRNA) is the RNA component of the 30S subunit of a prokaryotic ribosome . It binds to the Shine-Dalgarno sequence and provides most of the SSU structure. The genes coding for it are referred to as 16S rRNA genes and are used in reconstructing phylogenies , due to the slow rates of evolution of this region of the gene ...
Location of the MT-RNR2 gene on the H strand of the human mitochondrial genome. MT-RNR2 , or RRNL , is one of the two mitochondrial ribosomal RNA genes (blue boxes). Mitochondrially encoded 16S RNA (often abbreviated as 16S ) is the mitochondrial large subunit ribosomal RNA [ 1 ] [ 2 ] that in humans is encoded by the MT-RNR2 gene .
Oxford Nanopore Technologies plc is a UK-based company which develops and sells nanopore sequencing products (including the portable DNA sequencer, MinION) for the direct, electronic analysis of single molecules. [2] [3] [4] It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index. [5]
The company is headquartered on 11 hectares (26 acres) of industrial land in Kent, Washington, a suburb of Seattle, where its research and development is located.The facility was 24,000 m 2 (260,000 sq ft) in size in early 2015, [3] growing to 28,000 m 2 (300,000 sq ft) by March 2016 with Blue Origin leasing additional space in adjacent office buildings.
Sequencing technologies with a different approach than second-generation platforms were first described as "third-generation" in 2008–2009. [4]There are several companies currently at the heart of third generation sequencing technology development, namely, Pacific Biosciences, Oxford Nanopore Technology, Quantapore (CA-USA), and Stratos (WA-USA).